SEC Form 4 · accession 0001232524-17-000115
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Patrick Miller
Officer — EVP, US Commercial
Period of report
May 11, 2017
Accepted (ET)
May 15, 2017 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | May 11, 2017 | A | 1,000 | $0.00 | A | 22,623 | D | |
| Ordinary Shares | May 15, 2017 | S | 200 | $152.98 | D | 22,423 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $155.18 | May 11, 2017 | A | 2,500 | A | — | May 10, 2027 | Ordinary Shares | 2,500 | 2,500 | D |
Explanation of responses
- F1These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of June 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
- F2This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F3These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, May 11, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.